Biomerica, Inc. (BMRA)
After hours:
| Previous Close | 0.6653 |
| Open | 0.6870 |
| Bid | 0.6209 x 100 |
| Ask | 0.6858 x 100 |
| Day's Range | 0.6521 - 0.6870 |
| 52 Week Range | 0.5000 - 2.1300 |
| Volume | |
| Avg. Volume | 237,004 |
| Market Cap | 11.111M |
| Beta (5Y Monthly) | -0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inFoods IBS offers a groundbreaking method to identify foods that can trigger IBS symptoms, revolutionizing how IBS symptoms are managed. inFoods IBS is backed by extensive clinical research that has demonstrated r
- GlobeNewswire
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breastsFirst order placed for both Co
- GlobeNewswire
Biomerica provides update on inFoods® IBS expansion
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issue
